UK Markets closed

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
80.90+0.32 (+0.40%)
At close: 04:02PM EST
81.00 +0.10 (+0.12%)
After hours: 07:59PM EST
Sign in to post a message.
  • R
    Rajen
    A total of about 10M doses of Mol has been placed by different countries,most of them at about $700 per dose.I’m sure some countries like thailand & phill pines is paying a much cheaper price.I’m estimating about $4B to 5.5B revenues from these orders.Does anyone has any more info on this transactions?
  • R
    Real Immuno Investor 10
    $SLS conversation
    Last june around this time SLS traded up to 13 based $MRK $BMY results. Which, are also due right now with another 6 month accrual with more patients and most imp more time. The Keytruda trial will exceed the best available treatments. 100% of Gps patients were alive last time -at the 9 m median os, which is already equal to the BAT> Gps can only be better than the Best Available treatment, and its SAFETY PROFILE MAKES IT INSTANTLY APPROVABLE
    Very Similar set up to now.
  • k
    kC
    $SLS conversation
    2.5x trade volume, Friday was 1.75 x and 50% short, if today has another 50% - tomorrow will be back over 5 into the 6.5 range. SLS sitting on the launch pad for when Xbi finds a bottom - Investors will be getting paid, multiple times this year. 5 Value able inflection points with $mrk $bmy Fda meeting all in 2022.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Update 10 Catalysts, 3 ARE IMMINENT - No short squealing can dispute these facts.
    1. $MRK Keytruda Gps comb trial for Ovarian cancer patients, Pivotal / Binary results due to report now $ALKS rec’d Fda Fast Track for its combo
    2. $BMY Opdivo Gps for Mesothelioma patients, larger patient set, update on miracle cure patient
    3. $RHHBY Herceptin Gps Phase 2b $GLSI Twin Trial Due Now. Nct site updated in Nov w a DEC final Completion date
    4. Nps Outlicensing $250M potential Aug Ceo comment to 'stay tuned for a NPs announcement'. DEC Change of Control Filing
    5. VADIS DCIS Final Report over due A true vaccine to prevent ductal carcinoma for 65,000 US patients each year.
    6. Gps Phase 2/3 MRD+ Trial initiation/ news
    7. Aml Phase 3 Enrollment update
    8. Aml Phase 3 IDMC Statistical Efficacy analysis, possible halt for efficacy if they see a clear signal. Data 24 months on for a control group patient setting w a 5.5month os per Dr Levy in Aug, Baylor Medicals Hematologic Research Director.
    9. 3D Med $202 Milestone $$$ For the IND filed in JULY
    10. FDA Greenlight Gps for AML secondary Remission patients - 2nd half of 22 is worth about 2 b in market cap value. Cr2 is the first, initial indication, elderly patients in secondary remission median survival (21 months) 400% better than the standard treatment (5.5 months). Overall AML market expected to be approximately a billion in annual revenue. Over a Million patients with WT1 Cancer each year - GPS is a blockbuster waiting to happen.
  • f
    faruk
    Are you guys really still trading MRK? I have been been getting way better results using (http://Achieverspot.tech)
  • R
    Real Immuno Investor 10
    $SLS conversation
    Last week: MD Anderson Leukemia Chair Sees a 5 X expansion for Gps in AML, Ceo confirms Timelines
    1. $MRK Keytruda Gps comb trial for Ovarian cancer patients, Pivotal / Binary results due to report. 100% of gps patients were alive last update.
    2. SBMY Opdivo Gps for Mesothelioma patients. larger patient set, update on miracle cure patient
    3. $RHHBY Herceptin Gps Phase 2b $GLSI Twin Trial Due Now. Nct site updated in Nov w a DEC final Completion date
    4. ps Outlicensing $250M potential Aug Ceo comment to 'stay tuned for a NPs announcement' DEC Change of Control Filing
    5. VADIS DCIS Final Report over due A true vaccine to prevent ductal carcinoma for 65,000 US patients each year.
    6. Gps Phase 2/3 MRD+ Trial initiation/ news
    7. Aml Phase 3 Enrollment update
    8. Aml Phase 3 IDMC Statistical Efficacy analysis, possible halt for efficacy if they see a clear signal. Data 24 months on for a control group patient setting w a 5.5month os per Dr Levy in Aug, Baylor
    Medical Hematologic Research Director.
    9. 3D Med $202 Milestone $$$ For the IND filed in JULY
    10. FDA Greenlight Gps for AML secondary Remission patients - 2nd half of 22 is worth about 2 b in market cap value. Cr2 is the first, initial indication, elderly patients in secondary remission
    median survival (21 months) 400% better than the standard treatment (5.5 months). Overall AML market expected to be approximately a billion in annual revenue. Over a Million patients with WT1
    Cancer each year - GPS is a blockbuster waiting to happen.
  • R
    Real Immuno Investor 10
    $SLS conversation
    10 Catalysts, 3 ARE IMMINENT - Valuable data hits are now due
    1. $MRK Keytruda Gps comb trial for Ovarian cancer patients, Pivotal / Binary results due to report now $ALKS rec’d Fda Fast Track for its combo
    2. $BMY Opdivo Gps for Mesothelioma patients, larger patient set, update on miracle cure patient
    3. $RHHBY Herceptin Gps Phase 2b $GLSI Twin Trial Due Now. Nct site updated in Nov w a DEC final Completion date
    4. Nps Outlicensing $250M potential Aug Ceo comment to 'stay tuned for a NPs announcement'. DEC Change of Control Filing
    5. VADIS DCIS Final Report over due A true vaccine to prevent ductal carcinoma for 65,000 US patients each year.
    6. Gps Phase 2/3 MRD+ Trial initiation/ news
    7. Aml Phase 3 Enrollment update
    8. Aml Phase 3 IDMC Statistical Efficacy analysis, possible halt for efficacy if they see a clear signal. Data 24 months on for a control group patient setting w a 5.5month os per Dr Levy in Aug, Baylor Medicals Hematologic Research Director.
    9. 3D Med $202 Milestone $$$ For the IND filed in JULY
    10. FDA Greenlight Gps for AML secondary Remission patients - 2nd half of 22 is worth about 2 b in market cap value. Cr2 is the first, initial indication, elderly patients in secondary remission median survival (21 months) 400% better than the standard treatment (5.5 months). Overall AML market expected to be approximately a billion in annual revenue. Over a Million patients with WT1 Cancer each year - GPS is a blockbuster waiting to happen.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Double Triple or Instant Quad+ 10 Catalysts, 3 ARE IMMINENT
    1. $MRK Keytruda Gps comb trial for Ovarian cancer patients, Pivotal / Binary results due to report. 100% of gps patients were alive last update.
    2. SBMY Opdivo Gps for Mesothelioma patients. larger patient set, update on miracle cure patient
    3. $RHHBY Herceptin Gps Phase 2b $GLSI Twin Trial Due Now. Nct site updated in Nov w a DEC final Completion date
    4. ps Outlicensing $250M potential Aug Ceo comment to 'stay tuned for a NPs announcement' DEC Change of Control Filing
    5. VADIS DCIS Final Report over due A true vaccine to prevent ductal carcinoma for 65,000 US patients each year.
    6. Gps Phase 2/3 MRD+ Trial initiation/ news
    7. Aml Phase 3 Enrollment update
    8. Aml Phase 3 IDMC Statistical Efficacy analysis, possible halt for efficacy if they see a clear signal. Data 24 months on for a control group patient setting w a 5.5month os per Dr Levy in Aug, Baylor
    Medical Hematologic Research Director.
    9. 3D Med $202 Milestone $$$ For the IND filed in JULY
    10. FDA Greenlight Gps for AML secondary Remission patients - 2nd half of 22 is worth about 2 b in market cap value. Cr2 is the first, initial indication, elderly patients in secondary remission
    median survival (21 months) 400% better than the standard treatment (5.5 months). Overall AML market expected to be approximately a billion in annual revenue. Over a Million patients with WT1
    Cancer each year - GPS is a blockbuster waiting to happen.
  • V
    VirginiaLova
    $VTRS conversation
    Market realizes that VTRS is making 1) generic covid pill for $MRK 2) generic covid pill for $PFE 3) generic insulin with court rulings affirming their market position in the space 4) generic viagra 5) generic Epipen and a host of other revenue drivers.

    Also, if the BOD and management doesn't show investors an alpha performance to $24 a share, they are gone, finished, shareholders overwhelmingly rejecting the BOD and CEO.
  • E
    Ez$
    $SLS conversation
    10 Catalysts, 3 ARE IMMINENT Estimated Study Completion Date : December 2021 billions of Valuable data hits will be rendered:
    1. $MRK Keytruda Gps comb trial for Ovarian cancer patients, Pivotal / Binary results due to report now $ALKS rec’d Fda Fast Track for its combo
    2. $BMY Opdivo Gps for Mesothelioma patients, larger patient set, update on miracle cure patient
    3. $RHHBY Herceptin Gps Phase 2b $GLSI Twin Trial Due Now. Nct site updated in Nov w a DEC final Completion date
    4. Nps Outlicensing $250M potential Aug Ceo comment to 'stay tuned for a NPs announcement'. DEC Change of Control Filing
    5. VADIS DCIS Final Report over due A true vaccine to prevent ductal carcinoma for 65,000 US patients each year.
  • b
    bill
    If Keytruda has a role in clearance of dormant HIV, it leads to a similar thought of possible clearance of herpetic viruses by a similar mechanism, a much larger target disease. Just an obvious future study.
  • M
    Mike
    30 generic drug companies are partnered to produce and sell a low- cost version of Merck's new covid pill. Thoughts?
  • D
    Dennis
    Keytruda with FDA approval for tx of 16 different CA’s, expanding its use among oncology providers. Bless those (and their families) facing this diagnosis
  • F
    FEDERICO
    I believe the trend up will continue going into the report on Thursday, Feb. 3. which I also believe they will post a huge quarter, beat on revenue and beat on earnings, huge year overall and they will give a great outlook for another big year ahead for revenues and earnings, and continue increase in dividend pay.

    Heading to and ALL TIME HIGH of $100 per share and the Q4 and year end report will be the tailwind needed for MRK to become a great boring holding for at least the next 5 years that will provide great capital gains while getting paid along the way.

    Onward and Upward

    Blessings
  • D
    Defund-Secret Service
    Have you noticed the senior management departures under Fraiser?
    A CFO as heir apparent is not a good selection for a scientific company!
  • R
    Real Immuno Investor 10
    $SLS conversation
    Gps market opportunity expanded 5x in AML, SlS Science Chair confirms trial enrollment levels returned, Ceo Reconfirms ' Early 22 ' for $MRK $BMY pivotal results combining Gps with Keytruda /OPDIVO, $200M licensee pumps in another $15-$20M this year. STRONG BUY
  • S
    Stephens
    $SLS conversation
    Great Set up. The doctor running the Show from NYU went public about trial enrollment returning to normal. Phase 3 data that by all accounts is worth 10 times todays value will report in mere months. Will be a Huge Payday for SLS holders/buyers- if the idmc doesn’t halt for efficacy first or sls gets bought by $MRK or $BMY.
  • R
    Real Immuno Investor 10
    $SLS conversation
    Not if but when SLS shares are $100+ - Now is A Great Time to Invest in $SLS
    REGAL phase 3 compares Gps vs Existing SOC, Dr. Levy, Baylor Med Research Director for Hematology explained known SOC survival rates are 5/6 months. He also explained, (still online) all previous Gps trial data confirmed a strong and powerful Immune Response, that correlated to extended survival. Patients have more WT1 Cancer killing tcells and Live longer. Simple and straightforward. Existing treatments (defined on the NCT site for REGAL) have known outcomes. Gps has extended median overall survival in every single trial, in AML, Myeloma, Mesothelioma, Ovarian cancer. In the Moffit center phase 2 GPs extended Os to 21 months vs 5 wBAT.

    The IDMC is now reviewing and analyzing the Registrational phase 3 for Efficacy. In this open Label, single blind trial they are able to discontinue for Efficacy per the statistical analysis plan (SAP) if they see a clear signal, in this 24 month old trial.

    The AML Remission maintenance trial ($200M annual market) is the First of several cancers Gps treats, over 20.

    The SAP Registration includes a 10 month median OS FDA approval trigger for GPS vaccinated patients.

    SLS has partnerships with with $MRK $BMY, Gps is currently in combination w Keytruda and Opdivo - Results are now due for a Sponsor Investigated (MSKM) Mesothelioma Trial and a Pivotal Phase 2 Ovarian cancer trial.

    Let me know if you have any questions. I am a shareholder and have posted much dd.
  • T
    The REAL Chewdog
    DOG OF THE DOW--headed to 68-70. from a DECADES old LONG. Maybe they'll get bought buy a company with common sense who will instantly dismantle the BOD
  • R
    Real Immuno Investor 10
    $SLS conversation
    Not if, only when SLS shares trade for $100+ Jazz paid $1.5B for a lessor AML drug. $XBI beatdown is A Great Time to Invest. Dr. Levy, Baylor Med Research Director for Hematology explained AML SOC survival rates are 5/6 months. He also explained, (still online) all previous Gps trial data confirmed a strong and powerful Immune Response, that correlated to extended survival. Patients have more WT1 Cancer killing t cells and Live longer. Simple and straightforward. Existing treatments (defined on the NCT site for REGAL) have known outcomes. Gps has extended median overall survival in every single trial, in AML, Myeloma, Mesothelioma, Ovarian cancer. In the Moffit center phase 2 GPs extended Os to 21 months vs 5 wBAT.

    The IDMC is now reviewing and analyzing the Registrational phase 3 for Efficacy. In this open Label, single blind trial they are able to discontinue for Efficacy per the statistical analysis plan (SAP) if they see a clear signal, in this 24 month old trial.

    The AML Remission maintenance trial ($200M annual market) is the First of several cancers Gps treats, over 20.

    The SAP Registration includes a 10 month median OS FDA approval trigger for GPS vaccinated patients.

    SLS has partnerships with with $MRK $BMY, Gps is currently in combination w Keytruda and Opdivo - Results are now due for a Sponsor Investigated (MSKM) Mesothelioma Trial and a Pivotal Phase 2 Ovarian cancer trial.

    Let me know if you have any questions. I am a shareholder and have posted much dd.